2023 to 2024 Seasonal Influenza Vaccine Effective for Reducing Risk
By Elana Gotkine HealthDay Reporter
THURSDAY, Feb. 29, 2024 -- The 2023 to 2024 seasonal influenza vaccine is effective for reducing the risk for medically attended influenza virus infection, according to research published in the Feb. 29 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Aaron M. Frutos, Ph.D., from the CDC in Atlanta, and colleagues used a test-negative case-control study design to estimate the interim influenza VE during the 2023 to 2024 influenza season among patients aged 6 months and older with acute respiratory illness-associated medical encounters.
The researchers found that VE against influenza-associated outpatient visits and against hospitalization ranged from 59 to 67 percent and from 52 to 61 percent, respectively, among children aged 6 months to 17 years. VE against influenza-associated outpatient visits and against hospitalization ranged from 33 to 49 percent and from 41 to 44 percent, respectively, among adults aged 18 years and older. Across settings, VE against influenza A ranged from 46 to 59 percent and from 27 to 46 percent for children and adolescents and for adults, respectively. For pediatric patients in outpatient settings, VE against influenza B ranged from 64 to 89 percent; across settings, VE ranged from 60 to 78 percent for adults.
"These findings provide further evidence of the importance of influenza vaccination in reducing medically attended influenza illness in outpatient and inpatient settings among all age groups," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Higher COVID-19 Vaccination Rates Tied to Decrease in Childhood Asthma Symptoms
WEDNESDAY, July 3, 2024 -- Higher COVID-19 vaccination rates are associated with a lower prevalence of parent-reported childhood asthma symptoms, according to a research letter...
COVID-19 Vaccination Not Tied to Adverse Pregnancy Outcomes
TUESDAY, June 25, 2024 -- mRNA COVID-19 vaccination during pregnancy is not associated with an increased risk of adverse pregnancy outcomes, according to a study published in the...
FDA Approves Capvaxive Pneumococcal 21-Valent Conjugate Vaccine
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved the Capvaxive pneumococcal 21-valent conjugate vaccine for the prevention of invasive pneumococcal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.